April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Iván R. González: Denosumab vs. Zoledronic Acid in metastatic bone disease
Jan 26, 2025, 11:57

Iván R. González: Denosumab vs. Zoledronic Acid in metastatic bone disease

Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:

An interesting meta-analysis evaluates Denosumab vs. Zoledronic Acid in metastatic bone disease (MBD):An analysis of 7,441 patients compared both treatments, highlighting their therapeutic profiles:

Denosumab (Dmab):

Greater efficacy in reducing skeletal-related events (SREs), such as bone radiotherapy and pathological fractures (39% fewer in breast cancer).

Prolongs SRE-free intervals in most cancers.

Favorable safety profile: less renal toxicity and acute-phase reactions.

Delays pain progression and improves quality of life.

Considerations:Higher cost.

Risk of hypocalcemia and jaw osteonecrosis.

Zoledronic Acid (ZA):

A more cost-effective alternative in many contexts with comparable benefits in overall survival and disease progression.

While Dmab offers clinical advantages, the cost-effectiveness of both agents varies depending on cancer type and healthcare systems. Further research is essential to explore pain management, quality of life, and economic value to optimize MBD treatment.

Iván R. González: Denosumab vs. Zoledronic Acid in metastatic bone disease